A Phase 3 clinical trial studying cagrilintide and CagriSema in children and adolescents with excess body weight is now recruiting, as of August 31, 2026. The study, registered as NCT07253285, is titled "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight." Cagrilintide is related to calcitonin, an approved compound. The trial status is listed as recruiting, and it is designated a Phase 3 study. No results have been posted for this trial at this time. The trial record does not specify additional details beyond its phase, status, and recruitment update. Readers should note that recruiting status means the study is actively enrolling participants but has not yet reported outcomes. For more background on calcitonin, including its regulatory status and general information, readers can consult the compound overview.
Phase 3 Trial of Cagrilintide, CagriSema in Youth Begins Recruiting
See the full calcitonin overview
Source: https://clinicaltrials.gov/study/NCT07253285